269216
Costs of diabetes care over time: Changes and components
Tuesday, October 30, 2012
Thomas Hoerger, PhD
,
Center of Excellence in Health Promotion Economics, RTI International, Research Triangle Park, NC
Sean Simpson, MA
,
Public Health Policy Research Program, RTI International, Research Triangle Park, NC
For Americans with diabetes, the increased level of medical care required to treat diabetes means a higher level of related expenditures. To identify how much higher expenditures are for diabetes, and how this excess expenditure has changed over time, we evaluated nine years of MEPS Household Component data. We find that total expenditures increased more for persons with diabetes than for persons without diabetes, by roughly 17% over the nine years of data, with an estimated excess effect of $4,121 (2010 USD) in 2000 to $5,140 in 2003; the excess remained close to $5,000 throughout the remaining period. Prescription medication expenditures are the largest driver of this increase in cost ; the marginal effect of diabetes on prescriptions filled increased over this time period (20 additional prescriptions in 2000, vs 23 in 2008). Among other evaluated categories, the effect of diabetes has remained relatively stable over time. The marginal effect on office-based provider visits remained between 3.4 and 3.9 additional visits per year, with the marginal effect on related expenditures increasing from $658 in 2000 to a high of $861 in 2007, but generally remaining around $800 from 2004 onward. The effect of diabetes on hospital events is rather muted, with slight effects upon inpatient stays and emergency department visits and a somewhat greater effect on outpatient visits. Overall, diabetes leads to about 1 additional hospital event per year, and expenditures on hospital events for persons with diabetes are about $2,000 per year greater than for persons without diabetes.
Learning Areas:
Biostatistics, economics
Chronic disease management and prevention
Provision of health care to the public
Public health or related public policy
Learning Objectives: Describe the costs of diabetes in the United States over time.
Keywords: Diabetes, Economic Analysis
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I have directed a number of studies on the costs of diabetes and the cost-effectiveness of interventions to prevent diabetes and its complications.
Any relevant financial relationships? Yes
Name of Organization |
Clinical/Research Area |
Type of relationship |
Centers for Disease Control and Prevention |
Diabetes, hepatitis, chronic diseases |
Independent Contractor (contracted research and clinical trials) |
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|